Challenges in OINDPs Achieving Q3 Equivalence
Nanopharm review the bioequivalence challenges for OINDPs by achieving Q3 structural equivalence.
Challenging the Bioequivalence Hurdles for OINDPs: Achieving Q3 Structural Equivalence
Explore challenges in OINDP drug development, focusing on achieving bioequivalence in generic nasal formulations.
Characterizing Nasal Suspensions for Regulatory and Scientific Purposes
Explore Nanopharm’s in-depth research on particle size and its role in in vitro bioequivalence for nasal drug delivery. Discover how particle sizing impacts regulatory compliance and drug efficacy.
Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers
Explore Nanopharm’s in-depth in vitro study on dry powder inhalers (DPIs). Learn how Computational Fluid Dynamics and Particle Size Distribution contribute to device performance and comparability.
The Influence of Secondary Processing on the Structural Relaxation Dynamics of Fluticasone Propionate
Nanopharm explores structural dynamics of Fluticasone Propionate in DPIs. Focus on APSD in Dry Powder Inhaler formulations.
Structural Dynamics of Fluticasone Propionate Processing
Nanopharm explores the effect of secondary processing on the structural relaxation dynamics of Fluticasone Propionate.
Secondary Processing’s Effect on Fluticasone Dynamics
Explore the effect of secondary processing on the structural relaxation dynamics of Fluticasone Propionate in DPIs.
Advanced microscopy techniques to assess solid-state properties of inhalation medicines
Unveil Nanopharm’s expertise in advanced microscopy for OINDP. Explore solid-state analysis and its impact on inhalation medicines, including dry powder inhalers.
Cohesive-Adhesive Balances in DPIs
Explore Dry Powder Inhaler development through Atomic Force Microscopy. Uncover Cohesive-Adhesive balances in OINDP for effective inhaler formulations.
